JPH054074B2 - - Google Patents
Info
- Publication number
- JPH054074B2 JPH054074B2 JP57156229A JP15622982A JPH054074B2 JP H054074 B2 JPH054074 B2 JP H054074B2 JP 57156229 A JP57156229 A JP 57156229A JP 15622982 A JP15622982 A JP 15622982A JP H054074 B2 JPH054074 B2 JP H054074B2
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cells
- mouse
- antibody
- cultured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004027 cell Anatomy 0.000 claims description 121
- 210000004408 hybridoma Anatomy 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 16
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 15
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 15
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 15
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims description 14
- 108010093013 HLA-DR1 Antigen Proteins 0.000 claims description 13
- 108010029172 HLA-DR9 antigen Proteins 0.000 claims description 13
- 210000004988 splenocyte Anatomy 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 229940027941 immunoglobulin g Drugs 0.000 claims description 10
- 108010001041 HLA-DR7 Antigen Proteins 0.000 claims description 8
- -1 HLA-8wDRw6Y Proteins 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 239000002609 medium Substances 0.000 description 18
- 231100000263 cytotoxicity test Toxicity 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 239000012228 culture supernatant Substances 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 210000004748 cultured cell Anatomy 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 5
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 229940056360 penicillin g Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 229960002385 streptomycin sulfate Drugs 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57156229A JPS5944325A (ja) | 1982-09-07 | 1982-09-07 | 単クロ−ン性抗体およびそれらを産生するハイブリド−マ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57156229A JPS5944325A (ja) | 1982-09-07 | 1982-09-07 | 単クロ−ン性抗体およびそれらを産生するハイブリド−マ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5944325A JPS5944325A (ja) | 1984-03-12 |
| JPH054074B2 true JPH054074B2 (de) | 1993-01-19 |
Family
ID=15623178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57156229A Granted JPS5944325A (ja) | 1982-09-07 | 1982-09-07 | 単クロ−ン性抗体およびそれらを産生するハイブリド−マ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5944325A (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0239102A3 (de) * | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Verfahren zur Herstellung eines Human-Human-Hybridoms |
-
1982
- 1982-09-07 JP JP57156229A patent/JPS5944325A/ja active Granted
Non-Patent Citations (3)
| Title |
|---|
| J.IMMUNOL=1980 * |
| J.IMMUNOL=1981 * |
| PROC.NATL.ACAD.SCI=1979US * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5944325A (ja) | 1984-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI75363C (fi) | Foerfarande foer framstaellning av en monoklonal antikropp mot maenniskans hjaelpar-t-celler, medelst en ny hybridcellinje. | |
| FI75183C (fi) | Foerfarande foer framstaellning av en komplement-bindande monoklonal antikropp mot maenniskans t-celler genom anvaendning av en ny hybridcellinje. | |
| JP2648419B2 (ja) | モノクローナル抗体混合物 | |
| Lake et al. | Production and characterization of cytotoxic Thy‐1 antibody‐secreting hybrid cell lines Detection of T cell subsets | |
| EP0043718B1 (de) | Zellinien | |
| RU2202615C2 (ru) | Моноклональное антитело, способное распознавать антиген, вызывающий апоптоз миелоидных клеток костного мозга, и обладающее свойством вызывать апоптоз миеломных клеток, его фрагмент и гибридома | |
| JPS63294779A (ja) | ハイブリドマ | |
| JPH0690753A (ja) | ハイブリドーマセルラインの製造法 | |
| CA1201396A (en) | Process for the preparation of permanent animal and human cell lines and their use | |
| FI75598B (fi) | Foerfarande foer framstaellning av en monoklonal antikropp mot en maensklig tymocytantigen medelst en ny hybridcellinje. | |
| US4618585A (en) | Hybridoma cell lines producing monoclonal antibodies directed against cervical cancer cells | |
| JPH054074B2 (de) | ||
| KR900007950B1 (ko) | 모노클로날 항체의 제조방법 | |
| JPS6081130A (ja) | 抗ｈｌａ−ａ２抗体およびそれを産生するハイブリド−マ | |
| EP0393062A1 (de) | Monokonaler antikörper, der ein epitop der gammakette der menschlichen t-zell-oberflächenrezeptoren erkennt | |
| JPH05176790A (ja) | 脳ミオシンに対するモノクローナル抗体 | |
| JP3043629B2 (ja) | 抗体１０３ｂ２ | |
| Faraggiana et al. | Antibody formation and transient immune complex glomerulopathy in A-strain mice with C1300 neuroblastoma tumors | |
| JPH06319585A (ja) | 抗体およびその製造法 | |
| JPS59186923A (ja) | ヒト前立腺癌治療用薬剤 | |
| EP0370768A2 (de) | Monoklonaler Antikörper gegen das für Schilddrüsenkarzinom spezifische Antigen | |
| CS276448B6 (cs) | Způsob výroby permanentních buněčných lini-í živočišného i lidského původu | |
| SK281965B6 (sk) | Monoklonálna protilátka inhibujúca zachytávanie krvotvorných kmeňových buniek a hybridóm | |
| JPS59186925A (ja) | カンジダ菌感染症治療用薬剤 | |
| JPS63185374A (ja) | ヒト−ヒトハイブリド−マ作製用親細胞株 |